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ABSTRACT
This study compared the clinical presentations of 58 episodes of cryptococcosis in 50 patients and 26
episodes of penicillosis in 25 patients infected with human immunodeﬁciency virus (HIV) between June
1994 and June 2004, and assessed the safety of discontinuation of secondary prophylaxis for endemic
fungal infections in those patients responding to highly active anti-retroviral therapy (HAART).
Neurological symptoms were seen more commonly in patients with cryptococcosis, whereas respiratory
symptoms, lymphadenopathy, hepatomegaly and ⁄ or splenomegaly, and non-thrush-related oral
presentations were seen more commonly in patients with penicillosis. Patients with penicillosis were
more likely to have abnormal chest radiography results and radiographic presentations of interstitial
lesions, cavitations, ﬁbrotic lesions and mass lesions. At the end of the study, maintenance antifungal
therapy had been discontinued in 27 patients with cryptococcosis and in 18 patients with penicillosis in
whom the median CD4 count had increased to 186 cells ⁄ lL (range, 9–523 cells ⁄lL) and 95 cells ⁄ lL
(range, 15–359 cells ⁄ lL), respectively, after HAART. Only one episode of penicillosis recurred (a relapse
rate of 1.72 ⁄ 100 person-years; 95% CI, 1.44–2.10 ⁄ 100 person-years) after a median follow-up duration of
35.3 months (range, 2.6–91.6 months). No relapses occurred in patients with cryptococcosis after a
median follow-up duration of 22.3 months (range, 1–83.4 months). These ﬁndings suggest that there are
differences in the clinical presentations between endemic cryptococcosis and penicillosis in patients with
HIV infection, and that it is safe to discontinue secondary antifungal prophylaxis for cryptococcosis and
penicillosis in patients responding to HAART.
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INTRODUCTION
Clinical manifestations of invasive endemic fun-
gal infections caused by Cryptococcus neoformans
and Penicillium marneffei may be similar, resulting
in difﬁculties in distinguishing between these two
diseases in patients infected with human immuno-
deﬁciency virus (HIV) who travel to or reside in
endemic areas, such as Southeast Asia. However,
comparisons between these two diseases are
reported rarely in the literature.
Following the introduction of highly active
anti-retroviral therapy (HAART), the mortality
and morbidity [1,2], as well as the incidence of
AIDS-deﬁning opportunistic infections (OIs) [3],
have been reduced signiﬁcantly [4]. Discontinu-
ation of primary and secondary prophylaxis is
safe for many OIs in HIV-infected patients whose
immunity has been restored by HAART. Such OIs
include Pneumocystis carinii pneumonia (Pneumo-
cystis jiroveci pneumonia) [5–9], cytomegalovirus
end-organ disease, disseminated Mycobacterium
avium complex infection, and cerebral toxo-
plasmosis [10]. Discontinuation of secondary
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prophylaxis associated with invasive fungal infec-
tions has been reported for disseminated histo-
plasmosis [11], cryptococcal meningitis [12,13]
and penicillosis [14]. Despite the dramatic decline
in morbidity and mortality during the post-
HAART era, OIs continue to occur in patients
who are unaware of their HIV status, have limited
access to HIV care, or show poor adherence to
antimicrobial prophylaxis and HAART regimens.
Therefore, it remains important for physicians to
make timely diagnoses, based on clinical presen-
tation and microbiological cultures, in order to
start effective therapy.
The aims of the present study were to deter-
mine the clinical indicators required to differen-
tiate between cryptococcosis and penicillosis in
HIV-infected patients, and to assess the safety of
discontinuation of secondary prophylaxis for
cryptococcosis and penicillosis in HIV-infected
patients responding to HAART.
MATERIALS AND METHODS
Between June 1994 and June 2004, 1047 HIV-infected patients
sought medical care at the National Taiwan University
Hospital, Taipei. A standard case record form was used to
prospectively record patient demographics, AIDS-deﬁning
OIs, anti-retroviral therapy, antimicrobial therapy and labor-
atory test results, including plasma HIV RNA load (Amplicor
v. 1.5; Roche, Branchburg, NJ, USA) and CD4+ cell count [15].
Patients were enrolled in the study if a diagnosis of crypto-
coccosis and penicillosis was made. Clinical presentations,
concurrent OIs, relevant laboratory results, treatment course
and overall outcome (alive, relapse, death or loss to follow-up)
of endemic fungal infections were recorded. Cryptococcosis
was diagnosed if cultures of clinical specimens were positive
for C. neoformans, or if India ink smears were positive, or if
elevated cryptococcal antigen titres were present in the clinical
specimens. Penicillosis was diagnosed if cultures of clinical
specimens were positive for P. marneffei.
For patients with cryptococcosis, amphotericin B was
prescribed at a daily dosage of 0.7–1.0 mg ⁄ kg as induction
therapy for 2–3 weeks, followed by maintenance therapy with
oral ﬂuconazole 400 mg daily. For patients with penicillosis,
amphotericin B was prescribed at a daily dose of 0.7–
1.0 mg ⁄kg for 2 weeks, followed by itraconazole 400 mg daily
for 6–8 weeks. Survivors continued to receive HAART and
itraconazole 200 mg daily as maintenance therapy. Relapse
was diagnosed from clinical specimens by positive cultures or
India ink smears for C. neoformans, or positive cultures for
P. marneffei. Some of the cases included in this study have been
reported previously [14,16].
HAART was deﬁned as anti-retroviral therapy consisting of
at least one protease inhibitor or non-nucleoside reverse
transcriptase inhibitor, or abacavir plus two nucleoside reverse
transcriptase inhibitors. All HIV-infected patients were given
free access to HAART, which was introduced in Taiwan on
1 April 1997. The decision to discontinue maintenance therapy
was at the discretion of the treating physicians. At discontinu-
ation, data were collected concerning duration of antifungal
and antiviral therapies, CD4 counts and plasma HIV RNA
load. Clinical outcome was assessed on 31 December 2004, or
at date of death or loss to follow-up.
All statistical analyses were performed with SAS software
v. 8.1 (SAS Institute Inc., Cary, NC, USA) and Microsoft Ofﬁce
2003. Categorical variables were compared using v2 or Fisher’s
exact test. Non-categorical variables were compared using
Wilcoxon’s rank sum test, and p values < 0.05 were considered
signiﬁcant. To estimate the mortality rate in the pre-HAART
era (before 1 April 1997) and that in the post-HAART era (after
1 April 1997) in both groups, deaths of patients enrolled before
1 April 1997 were censored 6 months later, and for patients
enrolled after 1 April 1997, deaths were censored 6 months
after the end of study enrolment on 30 June 2004. The overall
mortality rate for each group was calculated as the number of
deaths ⁄ 100 person-years (100 PY) from enrolment to the end
of this study (31 December 2004), or to date of death or loss to
follow-up. Exact 95% CIs for mortality rates were calculated
on the basis of the Poisson distribution. The survival proba-
bilities were estimated by the Kaplan–Meier method. The Cox
proportional-hazards model was used to compare the mortal-
ity of the two endemic fungal infections, with adjustment for
age, gender, year in which endemic fungal infection was
diagnosed (i.e., pre-HAART or post-HAART), and baseline
CD4+ lymphocyte count. Hazard ratios and 95% CIs of risk for
death between patients with cryptococcosis and those with
penicillosis were calculated. The relapse rate for each group
was calculated as the number of relapses ⁄ 100 PY of observa-
tion. Exact 95% CIs for relapse rates were also calculated on
the basis of the Poisson distribution.
RESULTS
During the 10-year study period, 58 episodes of
cryptococcosis and 26 episodes of penicillosis
were diagnosed in 50 and 25 HIV-infected
patients, respectively. Thirteen (22%) episodes
of cryptococcosis were diagnosed in 12 patients in
the pre-HAART era, and 45 (78%) episodes were
diagnosed in 38 patients in the post-HAART era.
Six (23%) episodes of penicillosis were diagnosed
in six patients in the pre-HAART era and 20
(77%) episodes were diagnosed in 20 patients in
the post-HAART era. The baseline clinical char-
acteristics are shown in Table 1. Patients with
penicillosis had a lower median CD4 count at
baseline compared with patients with cryptococ-
cosis (9.5 cells ⁄ lL vs. 25 cells ⁄ lL; p 0.009), and
were less likely to acquire HIV via homosexual
activity (36% vs. 66%; p 0.01).
The clinical and microbiological characteristics
at diagnosis of invasive endemic fungal infections
are shown in Table 2. Most cases were diagnosed
in patients with high plasma HIV RNA loads
(>5 log10 copies ⁄mL), reduced CD4 counts, and
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Table 1. Baseline characteristics and outcomes of patients
infected with human immunodeﬁciency virus (HIV) and
with endemic fungal infections caused by Penicillium
marneffei and Cryptococcus neoformans
Cryptococcosis Penicillosis p
No. patients (episodes) 50 (58) 25 (26)
Female ⁄male 1 ⁄ 49 5 ⁄ 20 0.007
Median baseline CD4 count,
cells/lL (range)
25 (1–798) 9.5 (1–122) 0.009
< 100, n (%) 46 (93.9) 23 (95.8) 0.80
100–199 1 (2.0) 1 (4.2)
‡ 200 2 (4.1) 0
Median baseline PVL log10
copies/mL (range) (patients
with available data)
5.39 (2.6-5.88) (29) 5.48 (2.6-5.99) (12) 0.68
Overseas Chinese, n (%) 7 (14) 7 (28) 0.14
Risk-factor for HIV, n (%)
Heterosexual 14 (28) 15 (60) 0.007
MSM 33 (66) 9 (36) 0.01
IDU 1 (2) 1 (4)
Transfusion 1 (2) 0 (0)
Unknown 1 (2) 0 (0)
Median age at diagnosis,
years (range)
36 (24–82) 33 (27–82) 0.27
Median interval between initiation
of effective treatment and
admission, days (range)
2 (1–36) 8 (1–41) 0.006
Overall outcome, episodes (%) 58 26
Pre-HAART period 13 (13 ⁄ 58, 22%) 6 (6 ⁄ 26, 23%) 0.95
Discontinuation 3 (3 ⁄ 13, 23%) 5 (5 ⁄ 6, 83%) 0.01
Alive without relapse 2 2
Alive with relapse 0 1
Death 1 2
Alive with relapse 1 (1 ⁄ 13, 8%) 0 (0 ⁄ 6, 0%) 0.49
Death 9 (9 ⁄ 13, 69%) 1 (1 ⁄ 6, 17%) 0.03
Before 30 Sept. 1997 6 1
Lost to follow-up 0 0
Post-HAART period 45 (45 ⁄ 58, 78%) 20 (20 ⁄ 26, 77%) 0.95
Discontinuation 24 (24 ⁄ 45, 53%) 14 (14 ⁄ 20, 70%) 0.21
Alive without relapse 17 9
Alive with relapse 0 0
Death 1 2
Lost to follow-up 6 3
Alive with relapse episodes 7 (7 ⁄ 45, 16%) 0 (0 ⁄ 20, 0%) 0.06
Death 12 (12 ⁄ 45, 27%) 5 (5 ⁄ 20, 25%) 0.89
Before 31 Dec. 2004 12 5
Lost to follow-up 1 (1 ⁄ 45, 2%) 0 (0 ⁄ 20, 0%) 0.50
Data unavailable 1 (1 ⁄ 45, 2%) 0 (0 ⁄ 20, 0%) 0.50
No treatment 0 (0 ⁄ 45, 0%) 1 (1 ⁄ 20, 5%) 0.13
Mortality rate within 2 weeks of
hospitalisation, episodes (%)
6 (6 ⁄ 58, 10.3%) 3 (3 ⁄ 26, 11.5%) 0.87
Related to fungal infection 5 (8.6) 1 (3.8) 0.43
Mortality rate within 10 weeks of
hospitalisation, episodes (%)
12 (20.7) 4 (15.4) 0.57
Related to fungal infection 5 (8.6) 1 (3.8) 0.43
Cause of death, episodes (%) 23 10
Related to fungal infection 6 (6 ⁄ 58, 10.3%) 1 (1 ⁄ 26, 3.8%) 0.32
Enrolled before HAART 2 0
Enrolled after HAART 4 1
Related to other OI 4 (4 ⁄ 58, 6.9%) 3 (3 ⁄ 26, 11.5%) 0.48
Unrelated to OI 8 (8 ⁄ 58, 13.8%) 4 (4 ⁄ 26, 15.4%) 0.85
Unknown 5 (5 ⁄ 58, 8.6%) 2 (2 ⁄ 26, 7.7%) 0.89
Mortality rate, no. of episodes ⁄
100 person-years (95% CI)
Overall 20.33 (19.53, 21.15) 12.46 (11.75, 13.21) 0.17
Pre-HAART 59.24 (55.01, 63.70) 9.46 (7.78, 11.40) < 0.05
Post-HAART a16.01 (15.19, 16.86) b13.98 (12.98, 15.04) 0.77
Hazard ratio (95% CI)
(cryptococcosis vs. penicillosis)
Overall
Adjustedc 1.377 (0.630, 3.009) 0.42
Pre-HAART
Adjusted 3.503 (0.355, 34.596) 0.28
Post-HAART
Adjusted 1.127 (0.406, 3.129) 0.82
HAART, highly active anti-retroviral therapy; IDU, intravenous drug user; PVL,
plasma HIV RNA load; MSM, men who have sex with men; OI, opportunistic
infection.
aPre- vs. post-HAART, p 0.002.
bPre- vs. post-HAART, p 0.71.
cAdjusted for age, gender, and baseline CD4+ count.
Table 2. Clinical and microbiological manifestations of
patients infected with human immunodeﬁciency virus and
cryptococcosis or penicillosis
Cryptococcosis Penicillosis p
Median CD4 at diagnosis
of fungal infection, cells ⁄ lL
(range)
24 (1–565) 5.5 (0–122) <0.001
< 100, n (%) 48 (90.6) 25 (96) 0.79
100–199 2 (3.8) 1 (4)
‡ 200 3 (5.7) 0
Geometric mean of
cryptococcal antigen level
at diagnosis (range)
(episodes with available data)
398.46 (0–131 072) (50) NA
Median PVL at diagnosis, log10
copies ⁄mL
(range) (episodes with data)
5.17 (1.7–5.88) (34) 5.54 (2.6–5.88) (14) 0.12
<5 log10, n (%) 15 (44.1) 3 (21) 0.20
Clinical manifestations, n (%)
Fever 48 (82.8) 24 (92.3) 0.25
Constitutional symptomsa 29 (50.0) 14 (53.8) 0.74
Respiratory symptoms 23 (39.7) 21 (80.8) <0.001
Neurological symptoms 43 (74.1) 4 (15.4) <0.001
Skin lesions 12 (20.7) 8 (30.8) 0.32
Lymphadenopathy 9 (15.5) 18 (69.2) <0.001
Hepatomegaly and ⁄ or
splenomegaly
3 (5.2) 7 (26.9) 0.004
Non-thrush-related
oral presentationsb
2 (3.4) 6 (23.1) 0.005
Other concurrent OI 28 (49.1) 14 (53.8) 0.69
Chest X-ray ﬁndings
Episodes with data 49 26
Normal, n (%) 20 (40.8) 2 (7.7) 0.003
Interstitial 14 (28.6) 15 (57.7) 0.01
Patch 7 (14.3) 3 (11.5) 0.74
Nodular 7 (14.3) 3 (11.5) 0.74
Consolidation 3 (6.1) 1 (3.8) 0.68
Mass 0 (0) 2 (7.7) 0.05
Cavitations 7 (14.3) 9 (34.6) 0.04
Pleural effusion 4 (8.2) 3 (11.5) 0.63
Fibrotic lesions 0 (0) 4 (15.4) 0.005
Site of detection, episodes (%)
Blood 52 ⁄ 55 (94.5)
Culture 34 ⁄ 52 (65.4) 16 ⁄ 25 (64) 0.91
Antigen 47 ⁄ 48 (97.9) NA
Lung biopsy 6 ⁄ 7 (85.7) 7 ⁄ 8 (87.5)
Culture 2 ⁄ 6 (33.3) 3 ⁄ 6 (50) 0.56
Pathology 4 ⁄ 5 (80) 4 ⁄ 4 (100) 0.28
Antigen 2 ⁄ 2 (100) NA
Sputum 1 ⁄ 26 (3.8)
Culture 1 ⁄ 26 (3.8) 9 ⁄ 15 (60) <0.001
Antigen 1 ⁄ 2 (50) NA
Bone marrow 4 ⁄ 8 (50) 11 ⁄ 14 (78.6)
Culture 4 ⁄ 5 (80) 10 ⁄ 11 (90.9) 0.54
Pathology 1 ⁄ 7 (14.3) 8 ⁄ 13 (61.5) 0.04
Antigen 0 ⁄ 1 (0) NA
CSF 42 ⁄ 55 (76.4) 0 ⁄ 2 (0)
Culture 40 ⁄ 55 (72.7) 0 ⁄ 2 (0) 0.03
Antigen 39 ⁄ 52 (75) NA
Skin 0 ⁄ 6 (0) 9 ⁄ 10 (90)
Culture 0 ⁄ 5 (0) 6 ⁄ 8 (75) 0.008
Pathology 0 ⁄ 5 (0) 6 ⁄ 8 (75) 0.008
Lymph node 2 ⁄ 3 (66.7) 5 ⁄ 5 (100)
Culture 1 ⁄ 3 (33.3) 5 ⁄ 5 (100) 0.04
Pathology 2 ⁄ 2 (100) 4 ⁄ 4 (100)
Oral ⁄pharyngeal lesions
Culture 0 ⁄ 3 (0) 4 ⁄ 8 (50) 0.13
Urine 3 ⁄ 11 (27.3) 0 ⁄ 6 (0)
Culture 1 ⁄ 11 (9.1) 0 ⁄ 6 (0) 0.45
Antigen 2 ⁄ 2 (100) NA
CSF, cerebrospinal ﬂuid; OI, opportunistic infection; PVL, plasma HIV RNA load;
NA, not applicable.
aConstitutional symptoms included malaise, weight loss, sweating and poor
appetite.
bNon-thrush-related oral presentations included oral ulcers, sore throat, and
dysphagia.
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other concurrent AIDS-deﬁning OIs. Patients with
penicillosis had signiﬁcantly lower CD4 counts
than patients with cryptococcosis (5.5 vs.
24 cells ⁄ lL; p < 0.001). In both groups, most
patients had fever, and half had constitutional
symptoms. While neurological symptoms were
seen more commonly in patients with cryptococ-
cosis (74.1% vs. 15.4%; p < 0.001), patients with
penicillosis were signiﬁcantly more likely to
present with respiratory symptoms (80.8% vs.
39.7%; p < 0.001), lymphadenopathies of the
neck, mediastinum and peri-aortic areas (69.2%
vs. 15.5%; p < 0.001), hepatomegaly and ⁄ or sple-
nomegaly (26.9% vs. 5.2%; p 0.004), and non-
thrush-related oral presentations (23.1% vs. 3.4%;
p 0.005). Skin lesions were seen with similar
frequency in each patient population, but only
patients with penicillosis were diagnosed from
skin investigations (90% vs. 0%; p < 0.001).
More patients with penicillosis had abnormal
chest radiography results compared with patients
with cryptococcosis (92.3% vs. 59.2%; p 0.003)
(Table 2). Although there were no speciﬁc radio-
graphic patterns, patients with penicillosis were
more likely to have interstitial lesions (57.7% vs.
28.6%; p 0.01), cavitations with greater severity
(34.6% vs. 14.3%; p 0.04), ﬁbrotic lesions (15.4%
vs. 0%; p 0.005) and mass lesions (7.7% vs. 0%;
p 0.05) than patients with cryptococcosis.
C. neoformans and P. marneffei were isolated
from various clinical specimens (Table 2). Diag-
nosis of cryptococcosis by culture from bone
marrow provided the highest sensitivity (80%),
followed by cerebrospinal ﬂuid (72.7%), blood
(65.4%), lung biopsy (33.3%) and lymph nodes
(33.3%). Pathology also provided good diagnostic
sensitivity with lymph node (100%) and lung
biopsy (80%) specimens. Culture of bone marrow
was more sensitive than pathology (80% vs.
14.3%; p 0.02), but the sensitivity of serum cryp-
tococcal antigen detection was higher than that of
culture for blood (97.9% vs. 65.4%; p < 0.001),
sputum (50% vs. 3.8%; p 0.02) and urine (100%
vs. 9.1%; p 0.005) specimens.
Diagnosis of penicillosis by culture provided
the highest diagnostic yield with lymph node
specimens (100%), followed by specimens from
bone marrow (90.9%), skin (75%), blood (64%),
sputum (60%), lung biopsy (50%) and oral and
pharyngeal lesions (50%). Examination of the
specimens by pathology also provided a high
diagnostic yield for lymph node (100%), lung
biopsy (100%), skin (75%) and bone marrow
(61.5%) specimens.
Antifungal agents were initiated earlier follow-
ing hospitalisation for patients with cryptococco-
sis than for patients with penicillosis (median
interval, 2 vs. 8 days; p 0.006) (Table 1). All
patients with cryptococcosis received antifungal
agents following admission. The mortality rate
within 2 weeks of hospitalisation with cryptococ-
cosis was 10.3% (6 ⁄ 58 patients), with a median
interval from admission to death of 5 days (range,
3–10 days). Among the six deaths, ﬁve were
caused directly by cryptococcosis, while the other
was caused by a pulmonary embolism. The
mortality rate within 10 weeks of hospitalisation
was 20.7% (12 ⁄ 58 patients), with a median inter-
val from admission to death of 14 days (range,
3–52 days). No deaths that occurred between the
third and the tenth weeks were caused by fungal
infection. At the end of the observation period,
the mortality rate in the pre-HAART era was
signiﬁcantly higher than that in the post-HAART
era for patients with cryptococcosis, i.e., 59.24 vs.
16.01 ⁄ 100 PY (p 0.002). This ﬁnding might be
related to the introduction of HAART, with fewer
non-fungal-related deaths (20.0% vs. 61.5%;
p 0.003) occurring in the post-HAART era.
The mortality rate within 2 weeks of hospital-
isation in patients with penicillosis was 11.5%
(3 ⁄ 26 patients), with the intervals from admission
to death being 7, 10 and 11 days, respectively. A
patient who died of pneumothorax on day 11 did
not receive antifungal therapy before the diagno-
sis of penicillosis, while the other two patients
died of pneumothorax and Pneumocystis carinii
pneumonia, respectively. The mortality rate with-
in 10 weeks of hospitalisation was 15.4% (4 ⁄ 26
patients), with the fourth death occurring from an
unknown cause on day 50 following admission.
At the end of the observation period, the mortality
rate of penicillosis was similar before and after the
introduction of HAART, i.e., 9.46 vs. 13.98 ⁄ 100 PY
(p 0.71).
The overall mortality rate was similar for the
cryptococcosis and penicillosis groups (20.33 vs.
12.46 ⁄ 100 PY; p 0.17). Although patients with
cryptococcosis had a higher mortality rate than
those with penicillosis in the pre-HAART era
(59.24 vs. 9.46 ⁄ 100 PY; p < 0.05), the adjusted
hazard ratios for death were similar between
patients with cryptococcosis and penicillosis
either before or after the introduction of HAART.
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The Kaplan–Meier survival estimates for crypto-
coccosis and penicillosis patients overall, and
before and after the introduction of HAART, are
shown in Fig. 1.
After HAART, maintenance therapy was dis-
continued for 27 episodes of cryptococcosis in 27
patients because of immune recovery (26 epi-
sodes) or loss to follow-up (one episode)
(Table 3). At discontinuation, four (20%) of the
20 patients with available cryptococcal antigen
data had achieved an undetectable level. The
median cumulative treatment durations for the 27
patients with cryptococcosis were 13 days (range,
0–46 days) of amphotericin B, 16.1 months (range,
4.3–39.4 months) of ﬂuconazole, and 18.7 months
(range, 4.2–71.9 months) of HAART. The median
CD4 count and plasma HIV RNA load at discon-
tinuation were 186 cells ⁄ lL (range 9–523) and
1.7 log10 copies ⁄mL (range 1.7–4.9), respectively;
most (87.5%) patients had CD4 counts
> 100 cells ⁄ lL, and 83.3% had a CD4 increase of
‡ 100 cells ⁄lL. At the end of the observation
period, six patients were lost to follow-up and
two patients died of pneumonia and an unknown
cause, respectively. Most patients had good
immune restoration, with a median CD4 count
of 238 cells ⁄ lL (range 17–750), and 11 of 12
patients with data available still had detectable
cryptococcal antigen. After a median observation
period of 22.3 months (range, 1–83.4 months),
there was no relapse (95% CI, 0–0.20 ⁄ 100 PY).
In the penicillosis group, antifungal mainten-
ance therapy was discontinued in 19 episodes in
18 patients because of immune recovery (14
episodes), abnormal liver function tests (two
episodes) or loss to follow-up (three episodes)
(Table 3). The median cumulative treatment
durations were 13 days (range, 0–24 days) of
amphotericin B, 10.8 months (range, 2.9–
18.9 months) of itraconazole, and 9.9 months
(range, 3–61.6 months) of HAART. At discontinu-
ation, the median CD4 count was 95 cells ⁄ lL.
Most (94.7%) patients with penicillosis had CD4
counts < 200 cells ⁄ lL at discontinuation of sec-
ondary antifungal prophylaxis, and ten (52.6%)
patients had CD4 counts < 100 cells ⁄lL. In com-
parison with patients with cryptococcosis, pa-
tients with penicillosis had a less robust increase
in CD4 count (89 vs. 159.5 cells ⁄ lL; p 0.004), with
signiﬁcantly fewer patients having an increase of
‡ 100 cells ⁄lL (42.1% vs. 83.3%; p 0.005). At the
end of the observation period, the median CD4
count was 245.5 cells ⁄lL (range, 1–558 cells ⁄ lL)
and the plasma HIV RNA load was 1.7 log10 cop-
ies ⁄mL (range, 1.7–5.86 log10 copies ⁄mL). At this
time, 12 patients remained alive without relapse;
four (21.1%) had died because of disseminated
M. avium complex infection, upper gastrointesti-
nal tract bleeding, pulmonary tuberculosis, and
acute renal failure, respectively, and two were lost
to follow-up. After a median duration of observa-
tion of 35.3 months (range, 2.6–91.6 months),
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Fig. 1. (A) Overall Kaplan–Meier survival estimates for
cryptococcosis and penicillosis patients. (B) Kaplan–Meier
survival estimates for cryptococcosis and penicillosis
patients before introduction of HAART. (C) Kaplan–Meier
survival estimates for cryptococcosis and penicillosis
patients after introduction of HAART.
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there was one relapse after discontinuation of
maintenance therapy for 329 days, probably
resulting from poor compliance with HAART;
the relapse rate for penicillosis was 1.72 ⁄ 100 PY
(95% CI, 1.44–2.10 ⁄ 100 PY).
DISCUSSION
Although patients with cryptococcosis and peni-
cillosis often presented with indistinguishable
symptoms, such as fever and constitutional
symptoms, neurological symptoms were seen
more frequently in patients with cryptococcosis,
while respiratory symptoms, lymphadenopathy,
hepatomegaly and ⁄ or splenomegaly, and non-
thrush-related oral presentations were more com-
mon in patients with penicillosis. Such ﬁndings
are consistent with previous reports of patients
with cryptococcosis [17] and penicillosis [18].
Patients with cryptococcosis often have neurolog-
ical signs and symptoms, such as headache (77%)
and nuchal rigidity (29%) [17], but such symp-
toms were not observed by Supparatpinyo et al.
[18] among patients with penicillosis.
Previous reports described skin lesions (71%),
hepatomegaly (51%) and splenomegaly (16%)
among penicillosis patients, but not among
cryptococcosis patients [17,18]. Skin specimens
were found to be more sensitive (90%) for
isolation of P. marneffei in a series of cases in
Thailand [18]. Although the patients belonging to
both groups in the present study had skin lesions
at similar frequencies (cryptococcosis 20.7% vs.
penicillosis 30.8%; p 0.32), only patients with
penicillosis had microbiological or histopatho-
logical evidence of skin invasion (75% vs. 0%;
p 0.008). Therefore, skin biopsy and culture are
likely to provide a higher diagnostic yield for
patients with penicillosis than for patients with
cryptococcosis.
Numerous HIV-associated pulmonary compli-
cations, including bacterial, fungal, protozoal and
Table 3. Clinical outcome for
patients infected with human
immunodeﬁciency virus and cryp-
tococcosis or penicillosis who dis-
continued secondary prophylaxis
Cryptococcosis Penicillosis p
No. of patients who discontinued antifungal agents (episodes) 27 (27) 18 (19)
Reasons for discontinuation, episodes (%)
Immune recovery 26 (96.3) 14 (73.7)
Lost to follow-up 1 (3.7) 3 (15.8)
Abnormal LFT 0 (0) 2 (10.5)
Median CD4 at discontinuation, cells ⁄ lL
(range) (episodes with data)
186 (9–523) (24) 95 (15–359) (19) 0.001
< 50, n (%) 1 (4.2) 5 (26.3) 0.01
50–99 2 (8.3) 5 (26.3) 0.01
100–199 11 (45.8) 8 (42.1)
200–349 7 (29.2) 0 (0)
‡ 350 3 (12.5) 1 (5.3)
Median increase of CD4 count at discontinuation,
cells ⁄ lL (range)
159.5 (8–381) 89 () 4 to 349) 0.004
Increase of CD4 ‡ 100, n (%) 20 (83.3) 8 (42.1) 0.005
Increase of CD4 ‡ 200 7 (29.2) 1 (5.3) 0.06
Median PVL at discontinuation, log10 copies ⁄mL (range)
(episodes with data)
1.70 (1.7–4.9) (23) 2.34 (1.7–5.23) (14) 0.18
PVL ‡ 400 copies ⁄mL, n (%) 2 (8.7) 3 (21.4) 0.35
PVL <5 log10 22 (95.65) 11 (91.67) 1.00
Geometric mean of cryptococcal Ag level at discontinuation
(range) (episodes with data)
38.5 (0–512) (20) NA
Patients with undetectable cryptococcal
antigen (episodes) (%)
4 (20)
Median duration of treatment at discontinuation
Amphotericin B, days (range) 13 (0–46) 13 (0–24) 0.72
Azole, months (range) 16.1 (4.3–39.4) 10.8 (2.9–18.9) 0.001
Total, months (range) 16.5 (4.3–40.9) 10.8 (3.3–19.4)
Median duration of HAART at discontinuation, months (range) 18.7 (4.2–71.9) 9.9 (3–61.6) 0.06
Median duration of observation, range (months) 22.3 (1–83.4) 35.3 (2.6–91.6) 0.08
Latest data, median (range)
CD4 cells ⁄ lL 238 (17–750) 245.5 (1–558) 0.72
CD8 cells ⁄ lL 839 (330–1979) 768 (115–1473) 0.23
PVL log10 copies ⁄mL 1.7 (1.7–4.99) 1.7 (1.7–5.86) 0.38
Geometric mean of cryptococcal Ag level 21.93 (0–256) NA
Outcome, episodes (%)
Alive without relapse 19 (70.4) 12 (63.2) 0.61
Alive with relapse 0 (0) 1 (5.3) 0.23
Dead 2 (7.4) 4 (21.1) 0.18
Lost to follow-up 6 (22.2) 2 (10.5) 0.30
Relapse rate, events ⁄ 100 patient-years (95% CI) 0 (0, 0.20) 1.72 (1.44, 2.10) 0.35
Ag, antigen; HAART, highly active anti-retroviral therapy; NA: not applicable; LFT, liver function test; PVL, plasma
HIV RNA load.
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mycobacterial infections, as well as neoplasms
and idiopathic conditions [19], can result in
cavitations, and the aetiology of cavitary lesions
may vary with geographical area and immune
status. On comparison of the two case series of
patients with cryptococcosis and penicillosis,
more cavitary lesions (14.6% vs. 0%) and intra-
thoracic adenopathies (10.4% vs. 0%) were
observed in patients with cryptococcosis [17] than
in patients with penicillosis [18]. However, con-
sistent with the respiratory symptoms, more
patients with penicillosis had abnormal chest
radiography ﬁndings, especially cavitation and
interstitial patterns, than those with cryptococco-
sis.
Although patients with penicillosis had a
greater degree of immunosuppression than pa-
tients with cryptococcosis, both at baseline and at
diagnosis of fungal infection in terms of CD4
counts, the 2-week, 10-week and overall mortality
rates of the two diseases were similar (Table 1). In
this study, a substantial (5 ⁄ 6) proportion of
patients died directly from cryptococcosis within
2 weeks of diagnosis, although initiation of anti-
fungal therapy was earlier for cryptococcosis than
for penicillosis. These deaths may be attributable
to the propensity of cryptococcosis to involve the
central nervous system, causing increased intra-
cranial pressure and related morbidity and mor-
tality [20,21]. During the subsequent follow-up,
most deaths in the two study populations were
caused by other OIs because of insufﬁcient
immune restoration after a short course of
HAART.
The present ﬁndings, along with those of
previous studies [12,13], support the recommen-
dation to discontinue secondary prophylaxis for
cryptococcosis when the CD4 cell count increases
to ‡ 100 cells ⁄mL after HAART [22]. Despite
detectable cryptococcal antigenaemia in 11 pa-
tients with cryptococcosis at the end of the
observation period, no relapse was detected after
antifungal therapy and HAART.
Compared with cryptococcal meningitis, the
optimal CD4 count to guide discontinuation of
antifungal prophylaxis for penicillosis remains
unclear, since it is a rare OI of HIV-infected
patients in developed countries. In the present
study, compared with patients with cryptococco-
sis, patients with penicillosis discontinued main-
tenance therapy at lower CD4 counts (95 vs.
186 cells ⁄lL; p 0.001) and had a shorter duration
of maintenance therapy (10.8 vs. 16.1 months;
p 0.001) (Table 3). Furthermore, 94.7% of patients
had a CD4 count of £ 200 cells ⁄lL, and ten
(52.6%) patients even had a CD4 count of
< 100 cells ⁄ lL, which is lower than current criter-
ia for discontinuation of therapy for any oppor-
tunistic disease [22]. Despite a lower CD4 count at
discontinuation of antifungal prophylaxis, the
relapse rate (1.72 ⁄ 100 PY; 95% CI 1.44–2.10) re-
mained low among the patients who continued to
receive HAART. The only relapse episode, with a
CD4 count of 10 cells ⁄lL, was attributed to poor
compliance with HAART. Therefore, it is suggest-
ed that cessation of secondary prophylaxis may
be considered for patients with penicillosis who
achieve a good immunological response to
HAART.
In conclusion, there are differences in the
clinical presentations of cryptococcosis and pen-
icillosis in patients with HIV infection and AIDS.
After appropriate management of acute infection,
it appears to be safe to discontinue secondary
prophylaxis for penicillosis and cryptococcosis in
patients with HIV infection and AIDS who
respond to HAART with immune reconstitution.
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